SHARE Adaptation Intervention for African-American Families
NCT ID: NCT07208162
Last Updated: 2025-10-06
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
NA
120 participants
INTERVENTIONAL
2025-08-19
2026-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
SHARE(D) Stage II: Alzheimer's Risk Disclosure Protocol Piloting
NCT04309500
The Senior Companion Program Plus
NCT03602391
Dementia-Friendly Faith Villages to Support African American Families
NCT04983693
Neighborhood-based Physical and Social Activity for Older Black Caregivers and People Living With Dementia
NCT05658328
A Non-pharmacological Intervention for Patients With Alzheimer's Disease and Family Caregivers (Care Partners Program)
NCT03333252
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Treatment (SHARE Dyadic Intervention)
Treatment group dyads are comprised of a PLWD with mild to moderate dementia and his/her preferred CG. Following recruitment and the consent process and screening, baseline telephone interviews (T1) with trained interviewers from the Benjamin Rose Institute on Aging will be completed separately with all CGs and PLWDs. Treatment group dyads will receive the culturally adapted SHARE intervention compromised of up to five, 60- 90-minute, curriculum-guided sessions with a SHARE Counselor over a 8-10 week period. A (T2) follow-up interview will be conducted approximately two weeks after treatment group dyads complete their final session;.
5+1 Adapted, early-stage dyadic care planning intervention
The intervention group will receive the adapted SHARE Dyadic program, consisting of five, 60-90-minute curriculum-guided sessions with a SHARE Counselor, plus one optional family session.
Control (Treatment as usual single session)
Control group dyads are comprised of a PLWD with mild to moderate dementia and his/her preferred CG. Following recruitment and the consent process and screening, baseline telephone interviews (T1) with trained interviewers from the Benjamin Rose Institute on Aging will be completed separately with all CGs and PLWDs. Control group participants will receive a treatment as usual equivalent: a standardized educational and resource single session with a packet of information. A (T2) follow-up interview will be conducted approximately approximately eight weeks after (T1) baseline interviews.
Counseling session and printed resources
Control group participants will receive a treatment as usual equivalent: a single, standardized educational and resource session with a packet of information.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
5+1 Adapted, early-stage dyadic care planning intervention
The intervention group will receive the adapted SHARE Dyadic program, consisting of five, 60-90-minute curriculum-guided sessions with a SHARE Counselor, plus one optional family session.
Counseling session and printed resources
Control group participants will receive a treatment as usual equivalent: a single, standardized educational and resource session with a packet of information.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Care-recipient lives at home.
* The caregiver (CG) and/or the person with dementia (PWD), or symptoms of memory loss must identify as African American.
* PWD must be at least 50 years old and CGs 18 or older,
* Ability to speak and read English,
* Experiencing signs and symptoms of mild to moderate dementia through family caregiver report on the Dementia Severity Rating Scale and meeting the National Institute on Aging and the Alzheimer's Association clinical criteria for probable AD.
Exclusion Criteria
* A traumatic brain injury
* Intellectual or developmental disability
* Individuals experiencing extreme difficulty adjusting and coping to the diagnosis • Individuals living in an institutional setting
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Institute on Aging (NIA)
NIH
Benjamin Rose Institute on Aging
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Silvia Orsulic-Jeras
Role: PRINCIPAL_INVESTIGATOR
Benjamin Rose Institute on Aging
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Benjamin Rose
Cleveland, Ohio, United States
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol
Document Type: Informed Consent Form
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
BRIA2025SHARE-ROYBAL
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.